U Of U Hospitals & Clinics
- Type
- Teaching hospital
- Where
- Salt Lake City, UT
- Medicare CCN
- 460009
- Received
- $25,198,249 in 2,422 records, 2020 ($2,412,497 general, $22,785,751 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 221 | $2,412,497 |
| 2020 | Research payment | 2,201 | $22,785,751 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,201 | $22,785,751 |
| Grant | 51 | $1,650,170 |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing educat | 5 | $224,800 |
| Education | 15 | $172,255 |
| Space rental or facility fees (teaching hospital only) | 62 | $158,700 |
| Consulting Fee | 13 | $126,952 |
| Gift | 16 | $39,667 |
| Royalty or License | 5 | $16,315 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 14 | $11,254 |
| Charitable Contribution | 39 | $9,383 |
| Entertainment | 1 | $3,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Allergan, Inc. | $62,182 | Research payment | In-kind items and services | A multi-centered, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety o | 2020 | |
| 2020-12-31 | Allergan, Inc. | $38,280 | Research payment | In-kind items and services | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-12-31 | ABBVIE INC. | $31,352 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M13-494 | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $11,357 | Research payment | In-kind items and services | A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Posit | 2020 | |
| 2020-12-31 | Ultragenyx Pharmaceutical Inc. | $10,280 | Research payment | Cash or cash equivalent | DOJOLVI Drug, Oral nutritional supplements | UX007-CL202 | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $10,259 | Research payment | Cash or cash equivalent | Advanced Imaging Research USMRI | 2020 | |
| 2020-12-31 | Carl Zeiss Meditec, Inc. | $9,101 | Gift | In-kind items and services | KINEVO Device, Surgical Visualization System | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $8,531 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $6,750 | Research payment | Cash or cash equivalent | MAGNETOM Prisma Device, MR - MRI | UtahDibellaCardioSoftwarePerfMR | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $4,218 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $3,750 | Research payment | Cash or cash equivalent | UtahWangOrthoCartilageMR | 2020 | |
| 2020-12-31 | Stryker Corporation | $2,208 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $2,063 | Research payment | Cash or cash equivalent | Utah2018MRIPR814Prescot | 2020 | |
| 2020-12-31 | Janssen Research & Development, LLC | $1,700 | Research payment | Cash or cash equivalent | A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or | 2020 | |
| 2020-12-31 | Janssen Research & Development, LLC | $1,573 | Research payment | Cash or cash equivalent | A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,562 | Research payment | Cash or cash equivalent | Utah2020MRIPR794Parker | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,510 | Research payment | Cash or cash equivalent | Utah2018MRIPR1086BKholmovski | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,500 | Research payment | Cash or cash equivalent | Utah2019MRIPR1041DiBella | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $938 | Research payment | Cash or cash equivalent | Utah2019MRiPR794Parker | 2020 | |
| 2020-12-31 | Masimo Corporation | $869 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $825 | Research payment | Cash or cash equivalent | Utah2019MRIPR1092Parker | 2020 | |
| 2020-12-31 | Masimo Corporation | $804 | Education | In-kind items and services | EMMA and ISA Device, Devices | 2020 | |
| 2020-12-31 | Allergan, Inc. | $804 | Research payment | In-kind items and services | Pediatric (12-17) Clinical Pharmacology/Efficacy/Safety Study | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $750 | Research payment | Cash or cash equivalent | Utah2019MRIPR785DiBella | 2020 | |
| 2020-12-31 | Stryker Corporation | $485 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $403 | Research payment | Cash or cash equivalent | Utah2020MRIPR1066Anderson | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $204 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III Open Label Randomized Study to Assess the Efficacy and Safety of Olaparib Lynparza Versus Enzalutamide or Ab | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $168 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $129 | Research payment | Cash or cash equivalent | S3000 HELX with Touch Control Device, US - Ultrasound Systems | Contract Enhanced Ultrasound Dev for Addl Applications | 2020 |
| 2020-12-31 | Masimo Corporation | $64 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Masimo Corporation | $64 | Education | In-kind items and services | SedLine Device, Devices | 2020 | |
| 2020-12-31 | Abbott Laboratories | $60 | Research payment | In-kind items and services | Infinity DBS Pulse Generators Device, Cardiac Arrhythmias and Heart Failure | Abbott DBS Registry of Outcomes for Indications Over Time (ADROIT) | 2020 |
| 2020-12-31 | Abbott Laboratories | $45 | Research payment | In-kind items and services | Infinity DBS Pulse Generators Device, Cardiac Arrhythmias and Heart Failure | Abbott DBS Registry of Outcomes for Indications Over Time (ADROIT) | 2020 |
| 2020-12-31 | Abbott Laboratories | $40 | Research payment | In-kind items and services | Infinity DBS Pulse Generators Device, Cardiac Arrhythmias and Heart Failure | Abbott DBS Registry of Outcomes for Indications Over Time (ADROIT) | 2020 |
| 2020-12-30 | ABBVIE INC. | $60,303 | Research payment | Cash or cash equivalent | M16-109 | 2020 | |
| 2020-12-30 | ABBVIE INC. | $6,416 | Research payment | Cash or cash equivalent | M15-566 | 2020 | |
| 2020-12-30 | ABBVIE INC. | $1,365 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M14-032 | 2020 |
| 2020-12-30 | ABBVIE INC. | $974 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M14-032 | 2020 |
| 2020-12-29 | Agios Pharmaceuticals, Inc. | $6,782 | Research payment | Cash or cash equivalent | AG348-C-006 | 2020 | |
| 2020-12-29 | Merck Sharp & Dohme LLC | $4,674 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-12-28 | SEAGEN INC. | $19,448 | Research payment | In-kind items and services | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2020 |
| 2020-12-28 | SEAGEN INC. | $18,993 | Research payment | In-kind items and services | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2020 |
| 2020-12-28 | Janssen Research & Development, LLC | $3,178 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-12-28 | Janssen Research & Development, LLC | $2,199 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-12-24 | Janssen Research & Development, LLC | $24,298 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-24 | Blueprint Medicines Corporation | $19,562 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2020 | |
| 2020-12-24 | Blueprint Medicines Corporation | $16,956 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2020 | |
| 2020-12-24 | Regeneron Pharmaceuticals, Inc. | $9,050 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2020 |
| 2020-12-24 | Janssen Research & Development, LLC | $3,022 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-24 | Janssen Research & Development, LLC | $1,660 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-23 | PFIZER INC. | $7,565 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDO | 2020 |
| 2020-12-23 | PFIZER INC. | $7,351 | Research payment | Cash or cash equivalent | MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT | 2020 | |
| 2020-12-23 | E.R. Squibb & Sons, L.L.C. | $6,845 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III NSCLC 1L combo | 2020 |
| 2020-12-23 | TAIHO ONCOLOGY, INC. | $1,500 | Research payment | Cash or cash equivalent | TAS-120 | 2020 | |
| 2020-12-23 | Gilead Sciences, Inc. | $981 | Research payment | Cash or cash equivalent | Cayston Drug, RESP | Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $60 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-12-22 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | V938 Biological, ONCOLOGY | Protocol Title A Phase 1,1b, Open label Clinical Study of Intratumoral,Intralesional Administration of V938 in Combinati | 2020 |
| 2020-12-22 | SEAGEN INC. | $6,112 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2020 |
| 2020-12-22 | Merck Sharp & Dohme LLC | $4,604 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-12-22 | JAZZ PHARMACEUTICALS INC. | $1,500 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PR | 2020 |
| 2020-12-22 | Takeda Pharmaceuticals U.S.A., Inc. | $800 | Research payment | Cash or cash equivalent | ADYNOVATE Biological, HEMATOLOGY | PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF P | 2020 |
| 2020-12-22 | JAZZ PHARMACEUTICALS INC. | $686 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PR | 2020 |
| 2020-12-22 | PFIZER INC. | $648 | Research payment | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-12-22 | JAZZ PHARMACEUTICALS INC. | $300 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PR | 2020 |
| 2020-12-21 | ABBVIE INC. | $18,890 | Research payment | Cash or cash equivalent | M17-327 | 2020 | |
| 2020-12-21 | Regeneron Pharmaceuticals, Inc. | $10,850 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | RANDOMIZED, CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVITREAL AFLIBERCEPT | 2020 |
| 2020-12-21 | Cochlear Americas | $9,768 | Research payment | In-kind items and services | Nucleus Device, Implantable hearing solution | Investigation of Advanced Speech Coding Strategies Using the Nucleus 24 Percutaneous Cochlear Implant | 2020 |
| 2020-12-21 | Janssen Research & Development, LLC | $8,481 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Effic | 2020 | |
| 2020-12-21 | Kite Pharma, Inc. | $8,140 | Research payment | Cash or cash equivalent | A Phase 1 Study Evaluating the Safety and Efficacy of MAGE - A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA- | 2020 | |
| 2020-12-21 | Janssen Research & Development, LLC | $1,573 | Research payment | Cash or cash equivalent | A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or | 2020 | |
| 2020-12-21 | Boston Scientific Corporation | $620 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | POCS IN PSC | 2020 |
| 2020-12-21 | GENZYME CORPORATION | $110 | Research payment | Cash or cash equivalent | HECTOROL Drug, Genetic Disease | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) | 2020 |
| 2020-12-18 | Luminex Corporation | $50,000 | Compensation for serving as faculty or as a speaker for an accredited or certified continuing educat | Cash or cash equivalent | 2020 | ||
| 2020-12-18 | Janssen Research & Development, LLC | $9,473 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-18 | Merck Sharp & Dohme LLC | $802 | Research payment | In-kind items and services | V938 Biological, ONCOLOGY | Protocol Title A Phase 1,1b, Open label Clinical Study of Intratumoral,Intralesional Administration of V938 in Combinati | 2020 |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-17 | Blueprint Medicines Corporation | $85,974 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2020 | |
| 2020-12-17 | Blueprint Medicines Corporation | $53,741 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2020 | |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $37,500 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A SAFETY AND PHARMACOKINETIC STUDY OF SINGLE AGENT REGN2810 IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR C | 2020 |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $24,480 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A SAFETY AND PHARMACOKINETIC STUDY OF SINGLE AGENT REGN2810 IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR C | 2020 |
| 2020-12-17 | Blueprint Medicines Corporation | $16,162 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2020 | |
| 2020-12-17 | Blueprint Medicines Corporation | $16,115 | Research payment | Cash or cash equivalent | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2020 | |
| 2020-12-17 | Blueprint Medicines Corporation | $12,665 | Research payment | Cash or cash equivalent | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2020 | |
| 2020-12-17 | PFIZER INC. | $12,006 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2020 | |
| 2020-12-17 | ABBVIE INC. | $10,843 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-12-17 | Merck Sharp & Dohme LLC | $8,225 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamid | 2020 |
| 2020-12-17 | Karyopharm Therapeutics Inc. | $7,776 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Gliob | 2020 |
| 2020-12-17 | ABBVIE INC. | $7,395 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M13-833 | 2020 |
| 2020-12-17 | Blueprint Medicines Corporation | $7,391 | Research payment | Cash or cash equivalent | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2020 | |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $6,480 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A SAFETY AND PHARMACOKINETIC STUDY OF SINGLE AGENT REGN2810 IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR C | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $6,213 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The | 2020 |
| 2020-12-17 | ROCHE DIABETES CARE, INC. | $4,366 | Research payment | Cash or cash equivalent | POC CoaguChek Meters, Strips and Accessories Device, Point of Care | RD003737 | 2020 |
| 2020-12-17 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-12-17 | PFIZER INC. | $1,260 | Research payment | Cash or cash equivalent | DAURISMO Drug, ONCOLOGY | AN OPENLABEL PHASE 1B STUDY OF PF04449913 GLASDEGIB IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATE | 2020 |
| 2020-12-17 | Medicines360 | $1,200 | Research payment | Cash or cash equivalent | Liletta Device, Obstetrics/Gynecology (Women's Health) | A Phase 3 multicenter, open-label study of a Levonorgestrel 52 mg Intrauterine System for the treatment of heavy Menstru | 2020 |
| 2020-12-17 | Incyte Corporation | $465 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-12-17 | Incyte Corporation | $315 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A SAFETY AND PHARMACOKINETIC STUDY OF SINGLE AGENT REGN2810 IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR C | 2020 |
| 2020-12-16 | Sarepta Therapeutics, Inc. | $15,269 | Research payment | Cash or cash equivalent | Vyondys 53 Drug, Genetic Disease | 4045-301 | 2020 |
| 2020-12-16 | E.R. Squibb & Sons, L.L.C. | $9,650 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Nivo ipi vs Nivo in Stage IIIb c or IV Adjuvant Melanoma | 2020 |
| 2020-12-16 | ARRAY BIOPHARMA INC | $6,415 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2020 |
| 2020-12-16 | PFIZER INC. | $5,311 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-12-16 | ARRAY BIOPHARMA INC | $4,250 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2020 |
| 2020-12-16 | Intercept Pharmaceuticals, Inc. | $3,007 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-16 | ARRAY BIOPHARMA INC | $2,500 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2020 |
| 2020-12-16 | Zimmer Biomet Holdings, Inc. | $625 | Research payment | Cash or cash equivalent | Hips-MyMobility Device, Hips | myMobility Phase 0 Clinical Study | 2020 |
| 2020-12-16 | ARRAY BIOPHARMA INC | $565 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2020 |
| 2020-12-16 | ARRAY BIOPHARMA INC | $390 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE | 2020 |
| 2020-12-16 | Merck Sharp & Dohme LLC | $350 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate MK-1986 in Inpatients Under 2 | 2020 |
| 2020-12-15 | E.R. Squibb & Sons, L.L.C. | $12,646 | Research payment | Cash or cash equivalent | Phase FIH CCR2-5 I II Safety Expansion | 2020 | |
| 2020-12-15 | BioFire Diagnostics, LLC | $12,286 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FILMARRAY DIRECT: RAPID DIAGNOSIS OF ANTIMICROBIAL-RESISTANT PATHOGENS FROM BLOOD | 2020 |
| 2020-12-15 | PFIZER INC. | $11,503 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB IN COMBINATION WITH BINIMETINIB WITH OR WITHOUT T | 2020 |
| 2020-12-15 | SEAGEN INC. | $9,496 | Research payment | In-kind items and services | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2020 |
| 2020-12-15 | ABBVIE INC. | $4,981 | Research payment | Cash or cash equivalent | M16-109 | 2020 | |
| 2020-12-15 | Agios Pharmaceuticals, Inc. | $3,062 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vorasidenib in Subjects with Recurrent, No | 2020 | |
| 2020-12-15 | Allergan, Inc. | $2,130 | Research payment | Cash or cash equivalent | A multi-centered, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety o | 2020 | |
| 2020-12-15 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome | 2020 | |
| 2020-12-15 | Allergan, Inc. | $869 | Research payment | Cash or cash equivalent | Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steato | 2020 | |
| 2020-12-15 | Incyte Corporation | $777 | Research payment | Cash or cash equivalent | A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome | 2020 | |
| 2020-12-15 | Incyte Corporation | $515 | Research payment | Cash or cash equivalent | A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome | 2020 | |
| 2020-12-15 | Incyte Corporation | $465 | Research payment | Cash or cash equivalent | A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome | 2020 | |
| 2020-12-15 | Incyte Corporation | $410 | Research payment | Cash or cash equivalent | A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome | 2020 | |
| 2020-12-15 | Incyte Corporation | $327 | Research payment | Cash or cash equivalent | A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome | 2020 | |
| 2020-12-15 | C. R. Bard, Inc. & Subsidiaries | $180 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | C. R. Bard, Inc. & Subsidiaries | $20 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | C. R. Bard, Inc. & Subsidiaries | $20 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | C. R. Bard, Inc. & Subsidiaries | $10 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | C. R. Bard, Inc. & Subsidiaries | $10 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-14 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The | 2020 |
| 2020-12-14 | PFIZER INC. | $10,000 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-14 | Janssen Research & Development, LLC | $7,585 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2020 | |
| 2020-12-14 | BioFire Diagnostics, LLC | $6,091 | Research payment | Cash or cash equivalent | SpotFire System Device, Clinical Diagnostics | SpotFire STIV Pilot Study | 2020 |
| 2020-12-14 | Agios Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | AG348-C-006 | 2020 | |
| 2020-12-12 | SEAGEN INC. | $19,448 | Research payment | In-kind items and services | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2020 |
| 2020-12-12 | SEAGEN INC. | $9,496 | Research payment | In-kind items and services | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2020 |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $17,125 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A SAFETY AND PHARMACOKINETIC STUDY OF SINGLE AGENT REGN2810 IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR C | 2020 |
| 2020-12-10 | Kite Pharma, Inc. | $16,985 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Thera | 2020 |
| 2020-12-10 | Agios Pharmaceuticals, Inc. | $14,357 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vorasidenib in Subjects with Recurrent, No | 2020 | |
| 2020-12-10 | Blueprint Medicines Corporation | $13,845 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2020 | |
| 2020-12-10 | Merck Sharp & Dohme LLC | $5,564 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The | 2020 |
| 2020-12-10 | Agios Pharmaceuticals, Inc. | $4,182 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vorasidenib in Subjects with Recurrent, No | 2020 | |
| 2020-12-10 | PFIZER INC. | $3,000 | Research payment | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | TRANSTHYRETINASSOCIATED AMYLOIDOSIS OUTCOMES SURVEY THAOS A GLOBAL MULTICENTER LONGITUDINAL OBSERVATIONAL SURVEY OF PATI | 2020 |
| 2020-12-10 | Blueprint Medicines Corporation | $2,426 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2020 | |
| 2020-12-10 | PFIZER INC. | $2,400 | Research payment | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | TRANSTHYRETINASSOCIATED AMYLOIDOSIS OUTCOMES SURVEY THAOS A GLOBAL MULTICENTER LONGITUDINAL OBSERVATIONAL SURVEY OF PATI | 2020 |
| 2020-12-10 | Aesculap, Inc. | $1,475 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A SAFETY AND PHARMACOKINETIC STUDY OF SINGLE AGENT REGN2810 IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR C | 2020 |
| 2020-12-10 | Aesculap, Inc. | $973 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $849 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $802 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $802 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A SAFETY AND PHARMACOKINETIC STUDY OF SINGLE AGENT REGN2810 IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR C | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $10,677 | Research payment | Cash or cash equivalent | MK-1454 Drug, ONCOLOGY | Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combinatio | 2020 |
| 2020-12-09 | Monteris Medical Corporation | $9,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Neuroblate Device, Neuroblate | 2020 | |
| 2020-12-09 | Gilead Sciences, Inc. | $8,926 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-12-09 | Plexxikon Inc. | $7,510 | Research payment | Cash or cash equivalent | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2020 | |
| 2020-12-09 | Merck Sharp & Dohme LLC | $5,655 | Research payment | Cash or cash equivalent | MK-1454 Drug, ONCOLOGY | Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combinatio | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $2,768 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2020 |
| 2020-12-09 | ABBVIE INC. | $1,750 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M13-833 | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $752 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2020 |
| 2020-12-08 | Orion Corporation | $4,840 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES) | 2020 | |
| 2020-12-08 | E.R. Squibb & Sons, L.L.C. | $1,955 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIB Non-Hodgkin's Lymphoma DLBCL mono | 2020 |
| 2020-12-07 | GENZYME CORPORATION | $5,483 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biw | 2020 | |
| 2020-12-07 | Bayer Healthcare Pharmaceuticals Inc. | $2,351 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-12-07 | Medtronic Vascular, Inc. | $1,423 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2020 |
| 2020-12-07 | PFIZER INC. | $969 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT | 2020 |
| 2020-12-07 | Bayer Healthcare Pharmaceuticals Inc. | $535 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-12-07 | Boston Scientific Corporation | $351 | Research payment | Cash or cash equivalent | SQ-RX PULSE GENERATOR Device, TACHY | S ICD PAS | 2020 |
| 2020-12-07 | Boston Scientific Corporation | $169 | Research payment | Cash or cash equivalent | SQ-RX PULSE GENERATOR Device, TACHY | S ICD PAS | 2020 |
| 2020-12-04 | Allergan, Inc. | $8,100 | Research payment | Cash or cash equivalent | XEN Device, GLAUCOMA | Outcomes of Ab-Externo XEN 45 Placement ? A New Delivery ? in Patients With Glaucoma: EXPAND Study | 2020 |
| 2020-12-04 | Janssen Research & Development, LLC | $4,634 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Effic | 2020 | |
| 2020-12-03 | PFIZER INC. | $22,333 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2020 | |
| 2020-12-03 | PFIZER INC. | $14,607 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB IN COMBINATION WITH BINIMETINIB WITH OR WITHOUT T | 2020 |
| 2020-12-03 | Edwards Lifesciences Corporation | $5,973 | Research payment | Cash or cash equivalent | Commence Study 2012-02 | 2020 | |
| 2020-12-03 | Agios Pharmaceuticals, Inc. | $2,320 | Research payment | Cash or cash equivalent | AG348-C-011 | 2020 | |
| 2020-12-03 | Takeda Pharmaceuticals U.S.A., Inc. | $2,199 | Research payment | Cash or cash equivalent | VONVENDI Biological, HEMATOLOGY | A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLE | 2020 |
| 2020-12-03 | Takeda Pharmaceuticals U.S.A., Inc. | $695 | Research payment | Cash or cash equivalent | VONVENDI Biological, HEMATOLOGY | A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLE | 2020 |
| 2020-12-03 | Janssen Research & Development, LLC | $483 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-12-03 | Merck Sharp & Dohme LLC | $59 | Research payment | In-kind items and services | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate MK-1986 in Inpatients Under 2 | 2020 |
| 2020-12-02 | Zimmer Biomet Holdings, Inc. | $3,786 | Research payment | Cash or cash equivalent | Knees-MyMobility Device, Knees | myMobility Phase 0 Clinical Study | 2020 |
| 2020-12-02 | ABBVIE INC. | $3,226 | Research payment | Cash or cash equivalent | M15-566 | 2020 | |
| 2020-12-02 | PFIZER INC. | $2,750 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF06804103 IN PATIENTS WITH HUMAN EPIDERMAL GR | 2020 | |
| 2020-12-02 | ABBVIE INC. | $2,697 | Research payment | Cash or cash equivalent | M16-109 | 2020 | |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | Travere Therapeutics, Inc. | $1,550 | Research payment | Cash or cash equivalent | (820) Cholbam Drug, Hepatology | The Replace Registry | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $375 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate MK-1986 in Inpatients Under 2 | 2020 |
| 2020-12-01 | Biogen, Inc. | $100,088 | Research payment | Cash or cash equivalent | SRA, University of Utah, Robert Welsh Ph.D and Vincent Kopplemans Ph.D, Determine ID# 241347 NO NPI, (CALSNIC Develop | 2020 | |
| 2020-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $800 | Research payment | Cash or cash equivalent | ADYNOVATE Biological, HEMATOLOGY | PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF P | 2020 |
| 2020-12-01 | Incyte Corporation | $165 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2020 | |
| 2020-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $75 | Research payment | Cash or cash equivalent | ADYNOVATE Biological, HEMATOLOGY | PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF P | 2020 |
| 2020-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $35 | Research payment | Cash or cash equivalent | ADYNOVATE Biological, HEMATOLOGY | PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF P | 2020 |
| 2020-11-30 | Vanda Pharmaceuticals Inc. | $5,275 | Research payment | Cash or cash equivalent | STUDY TO ASSESS THE EFFICACY OF VLY-686 IN RELIEVING SYMPTOMS OF GASTROPARESIS | 2020 | |
| 2020-11-30 | Janssen Research & Development, LLC | $2,500 | Research payment | Cash or cash equivalent | SELECT: Selexipag in inoperable or persistent/recurrent Chronic Thromboembolic pulmonary hypertension A multicenter, ran | 2020 |
The latest 200 records of 2,422.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Salt Lake City, UT, county Salt Lake County, UT, state Utah; placed by its city name.
| Measure | Place (city or town) Salt Lake City, UT | County Salt Lake County, UT | State Utah |
|---|---|---|---|
| Population B01003 | 208,007 | 1,196,523 | 3,392,331 |
| Population, 2020 census P1 | 199,723 | 1,185,238 | 3,271,616 |
| Median age B01002 | 32.9 | 34.0 | 32.0 |
| Under 18 B01001 | 16.4% | 25.3% | 27.8% |
| 65 and over B01001 | 12.5% | 11.9% | 11.9% |
| Households B11001 | 92,652 | 426,245 | 1,124,822 |
| Foreign born B05002 | 14.9% | 13.5% | 8.9% |
| Median household income B19013 | $75,090 | $97,494 | $95,166 |
| Median family income B19113 | $109,291 | $116,682 | $109,675 |
| Per capita income B19301 | $51,173 | $45,106 | $40,873 |
| Poverty rate B17001 | 13.6% | 8.1% | 8.5% |
| Unemployment rate B23025 | 4.2% | 3.8% | 3.6% |
| Civilian labor force B23025 | 129,830 | 670,900 | 1,778,106 |
| Mean commute (minutes) B08013 | 19.5 | 22.3 | 22.1 |
| Bachelor's degree or higher B15003 | 51.5% | 39.4% | 37.7% |
| Housing units B25001 | 101,188 | 449,662 | 1,223,468 |
| Owner-occupied B25003 | 45.8% | 66.1% | 70.2% |
| Renters B25003 | 54.2% | 33.9% | 29.8% |
| Median home value B25077 | $539,500 | $525,700 | $489,400 |
| Median gross rent B25064 | $1,414 | $1,592 | $1,496 |
| White, not Hispanic B03002 | 64.4% | 66.6% | 74.7% |
| Black B03002 | 2.3% | 1.7% | 1.1% |
| Hispanic or Latino B03002 | 20.8% | 20.6% | 15.9% |
| Asian B03002 | 4.9% | 4.2% | 2.4% |
| American Indian and Alaska Native B03002 | 0.5% | 0.5% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Salt Lake City, UT.
Comments